Stakeholder Insight: Breast Cancer Chemotherapy

Introduction

Based on Datamonitor’s Breast Cancer Insight survey results, which interviewed 580 leading breast cancer specialists across Europe, the US and Japan, in 2002, this In-Depth Analysis presents an impartial perspective on physicians' perceptions and prescribing trends in the chemotherapeutic treatment of breast cancer. 

Scope

Does the much-maligned CMF regime have a valuable role in patients that are vulnerable to cardiac events? 

In terms of anthracycline-based regimens, do doctors prefer either doxorubicin or epirubicin? 

Is there still a degree of resistance to the incorporation of taxanes into early-stage disease. If so, why? 

Report Highlights

Growth in the market is expected to be driven not only by the rising incidence of breast cancer, but also by the increasing use of chemotherapy in first line treatment. 

More comprehensive clinical trial data is needed to convince prescribers.  

Reasons to Purchase

Identify key issues for practicing cancer specialists the questions they really want the pharma industry to answer 

Explore the reasons, rational and emotional, behind cancer specialists' decisions 

Predict future trends and perception in the treatment of breast cancer patients 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a262